The clinical picture of TNBC is exacerbated by the inadequacy of its conventional treatments: endocrine and anti-HER2 therapies for hormone-receptor-positive and HER2-positive breast cancer are ineffective for TNBC patients due to their absence of hormone and HER2 receptors [8]. The gene discussed is ERBB2; the disease is breast carcinoma.